Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
7.49
USD
|
0.00%
|
|
-5.37%
|
+5.05%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,187
|
359.5
|
97.5
|
336.1
|
356.2
|
-
|
-
|
Enterprise Value (EV)
1 |
2,187
|
90.71
|
-63.78
|
336.1
|
356.2
|
356.2
|
356.2
|
P/E ratio
|
-
|
-7.95
x
|
-0.95
x
|
-3.48
x
|
-4.79
x
|
-4.54
x
|
-3.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
220
x
|
12
x
|
150
x
|
203
x
|
147
x
|
269
x
|
223
x
|
EV / Revenue
|
220
x
|
12
x
|
150
x
|
203
x
|
147
x
|
269
x
|
223
x
|
EV / EBITDA
|
-
|
-8.19
x
|
-0.97
x
|
-3.82
x
|
-4.2
x
|
-3.67
x
|
-3.06
x
|
EV / FCF
|
-63.6
x
|
-5.53
x
|
-0.92
x
|
-4.12
x
|
-4.81
x
|
-4.95
x
|
-3.39
x
|
FCF Yield
|
-1.57%
|
-18.1%
|
-109%
|
-24.3%
|
-20.8%
|
-20.2%
|
-29.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,727
|
42,247
|
42,391
|
47,137
|
47,551
|
-
|
-
|
Reference price
2 |
52.41
|
8.510
|
2.300
|
7.130
|
7.490
|
7.490
|
7.490
|
Announcement Date
|
3/15/21
|
3/15/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
9.887
|
9.934
|
30.02
|
0.652
|
1.657
|
2.418
|
1.325
|
1.6
|
EBITDA
1 |
-
|
-
|
-43.89
|
-100.3
|
-87.92
|
-84.82
|
-97.05
|
-116.3
|
EBIT
1 |
-
|
-36.93
|
-45.27
|
-103.3
|
-91.96
|
-86.56
|
-95.33
|
-141.5
|
Operating Margin
|
-
|
-371.76%
|
-150.81%
|
-15,848.01%
|
-5,549.61%
|
-3,579.75%
|
-7,194.82%
|
-8,840.84%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-44.97
|
-101.9
|
-87.3
|
-82.94
|
-97.33
|
-164.2
|
Net income
1 |
-
|
-
|
-44.97
|
-101.9
|
-87.3
|
-82.95
|
-97.33
|
-164.2
|
Net margin
|
-
|
-
|
-149.83%
|
-15,635.74%
|
-5,268.44%
|
-3,430.33%
|
-7,345.91%
|
-10,265.62%
|
EPS
2 |
-
|
-
|
-1.070
|
-2.410
|
-2.050
|
-1.565
|
-1.650
|
-2.205
|
Free Cash Flow
1 |
-
|
-34.39
|
-65.04
|
-106.1
|
-81.64
|
-74
|
-72
|
-105
|
FCF margin
|
-
|
-346.14%
|
-216.68%
|
-16,274.85%
|
-4,926.67%
|
-3,060.38%
|
-5,433.96%
|
-6,562.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/18/20
|
3/15/21
|
3/15/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
30.08
|
-
|
0.05
|
0.212
|
0.39
|
0.057
|
0.2
|
0.686
|
0.714
|
1.115
|
0.399
|
0.443
|
0.465
|
-
|
-
|
EBITDA
1 |
-
|
-23.69
|
-26.52
|
-24.3
|
-25.27
|
-20.65
|
-20.32
|
-27.58
|
-17.97
|
-19.07
|
-20.73
|
-21.58
|
-22.93
|
-
|
-
|
EBIT
1 |
9.246
|
-24.17
|
-27.66
|
-25.23
|
-26.28
|
-21.66
|
-22.75
|
-28.6
|
-18.95
|
-20.04
|
-21.08
|
-21.83
|
-22.58
|
-21
|
-21
|
Operating Margin
|
30.74%
|
-
|
-55,316%
|
-11,900.47%
|
-6,737.44%
|
-38,001.75%
|
-11,373.5%
|
-4,168.8%
|
-2,654.2%
|
-1,797.67%
|
-5,282.24%
|
-4,927.69%
|
-4,856.8%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-24.53
|
-27.37
|
-24.64
|
-25.41
|
-20.72
|
-21.35
|
-27.54
|
-17.69
|
-18.5
|
-20.47
|
-21.52
|
-22.43
|
-20
|
-20
|
Net income
1 |
-
|
-24.53
|
-27.37
|
-24.64
|
-25.41
|
-20.72
|
-21.35
|
-27.54
|
-17.69
|
-18.5
|
-20.47
|
-21.52
|
-22.43
|
-20
|
-20
|
Net margin
|
-
|
-
|
-54,742%
|
-11,620.28%
|
-6,515.64%
|
-36,357.89%
|
-10,673%
|
-4,014.72%
|
-2,477.17%
|
-1,659.55%
|
-5,129.82%
|
-4,857.9%
|
-4,822.69%
|
-
|
-
|
EPS
2 |
-
|
-0.5800
|
-0.6500
|
-0.5800
|
-0.6000
|
-0.4900
|
-0.5000
|
-0.6500
|
-0.4100
|
-0.3700
|
-0.4100
|
-0.3925
|
-0.3925
|
-0.3900
|
-0.3900
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/12/22
|
8/11/22
|
11/8/22
|
2/23/23
|
5/9/23
|
8/10/23
|
11/9/23
|
2/29/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
269
|
161
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-34.4
|
-65
|
-106
|
-81.6
|
-74
|
-72
|
-105
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-45.5%
|
-54.4%
|
-69.8%
|
-69.3%
|
-43.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
7.93
|
11.6
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
26.41%
|
1,781.29%
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/18/20
|
3/15/21
|
3/15/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
7.49
USD Average target price
15.5
USD Spread / Average Target +106.94% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.05% | 356M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|